To confirm that TRIM44 enhances the survival of MM cells by inducing autophagy, we treated TRIM44-expressing (TRIM44[OE]) MM cells with Bortezomib, both with and without 3MA (an autophagy inhibitor) and assessed the percentage of apoptotic cells through FACS analysis. This evidence concerns the gene TRIM44 and Miyoshi myopathy.